AURA Aura Biosciences, Inc.
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1501796 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-28.6%
TTM EPS YoY16.8%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-61.7%
ROA-53.5%
ROIC (approx.)-64.7%
Asset turnover—
Leverage & solvency
Liabilities / assets10.6%
Debt / equity0.00x
Current ratio14.21x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.80x
Accruals ratio-10.8%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | — | — | — | — | — |
| R&D expense | $90.30M | $73.30M | $65.23M | $42.24M | $25.16M |
| SG&A expense | $22.49M | $22.81M | $19.76M | $18.06M | $10.09M |
| Operating income | -$112.79M | -$96.12M | -$84.99M | -$60.30M | -$35.25M |
| Pretax income | -$106.08M | -$86.81M | -$76.27M | -$58.76M | — |
| Income tax | $108,000 | $112,000 | $137,000 | $0 | $0 |
| Net income | -$106.19M | -$86.92M | -$76.41M | -$58.76M | -$35.25M |
| EBITDA | -$111.66M | -$94.89M | -$83.70M | -$59.12M | -$34.42M |
| EPS (basic) | -1.76 | -1.75 | -1.93 | -1.96 | -8.95 |
| EPS (diluted) | -1.76 | -1.75 | -1.93 | -1.96 | -8.95 |
| Weighted avg. shares (diluted) | 60.34M | 49.65M | 39.62M | 29.94M | 5.16M |
| Balance sheet | |||||
| Cash & equivalents | $59.52M | $31.69M | $41.06M | $121.58M | $149.06M |
| Current assets | $149.74M | $160.62M | $231.79M | $196.70M | $153.70M |
| PP&E, net | $2.62M | $3.21M | $3.15M | $5.37M | $5.25M |
| Total assets | $169.43M | $182.50M | $255.07M | $223.94M | $160.03M |
| Current liabilities | $18.38M | $14.91M | $12.36M | $10.46M | $7.36M |
| Total liabilities | $32.52M | $30.53M | $29.23M | $28.35M | $7.71M |
| Shareholders' equity | $136.91M | $151.97M | $225.85M | $195.58M | $152.31M |
| Shares outstanding | 63.59M | 50.00M | 49.35M | 37.77M | 29.21M |
| Cash flow statement | |||||
| Operating cash flow | -$84.74M | -$79.81M | -$63.85M | -$54.60M | -$32.41M |
| Capital expenditure | $447,000 | $1.25M | $709,000 | $1.09M | $2.12M |
| Free cash flow | -$85.19M | -$81.06M | -$64.56M | -$55.70M | -$34.53M |
| Investing cash flow | $35.59M | $68.82M | -$113.96M | -$67.87M | -$2.12M |
| Financing cash flow | $77.16M | $1.59M | $97.29M | $95.63M | $166.26M |
| Depreciation & amortization | $1.13M | $1.22M | $1.29M | $1.18M | $831,000 |
| Stock-based compensation | $14.32M | $11.72M | $8.77M | $6.41M | $2.31M |
Free plan shows the latest 5 periods; Pro shows all 6 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.